1. Home
  2. ANGH vs LIXT Comparison

ANGH vs LIXT Comparison

Compare ANGH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anghami Inc.

ANGH

Anghami Inc.

N/A

Current Price

$3.45

Market Cap

25.4M

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$2.87

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGH
LIXT
Founded
2012
2005
Country
United Arab Emirates
United States
Employees
186
4
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
25.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ANGH
LIXT
Price
$3.45
$2.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.1K
34.3K
Earning Date
12-30-2025
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.64
52 Week High
$7.05
$6.09

Technical Indicators

Market Signals
Indicator
ANGH
LIXT
Relative Strength Index (RSI) 59.60 51.53
Support Level $2.83 $2.97
Resistance Level $3.46 $3.30
Average True Range (ATR) 0.24 0.28
MACD 0.07 0.02
Stochastic Oscillator 79.64 65.06

Price Performance

Historical Comparison
ANGH
LIXT

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: